Radius Health, a US-based developer of drug therapies, has postponed its flotation plans which were initially supposed to raise $86.2m for the company before being scaled back to $62m.
Radius Health, a developer of drug therapies for osteoporosis and women’s health, has postponed its initial public offering [IPO], citing market conditions. The company had planned to sell 6.5 million shares at between $8.50 and $10.50 per share, and trade on the Nasdaq, as stated in a filing in February. Investment banks UBS and Leerink Swann were to serve as co-lead underwriters.
Radius Health has raised over $170m in funding from firms including MPM Capital (389.2% pre-IPO stake), The…
